DE602006021600D1 - Verfahren zur senkung des blutdrucks - Google Patents

Verfahren zur senkung des blutdrucks

Info

Publication number
DE602006021600D1
DE602006021600D1 DE602006021600T DE602006021600T DE602006021600D1 DE 602006021600 D1 DE602006021600 D1 DE 602006021600D1 DE 602006021600 T DE602006021600 T DE 602006021600T DE 602006021600 T DE602006021600 T DE 602006021600T DE 602006021600 D1 DE602006021600 D1 DE 602006021600D1
Authority
DE
Germany
Prior art keywords
blood pressure
reducing
reducing blood
agents
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006021600T
Other languages
English (en)
Inventor
Parobok Ingrid Langsetmo
Todd W Seeley
Robert C Stephenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of DE602006021600D1 publication Critical patent/DE602006021600D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Fuel Cell (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602006021600T 2005-09-29 2006-05-05 Verfahren zur senkung des blutdrucks Active DE602006021600D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72230205P 2005-09-29 2005-09-29
PCT/US2006/017507 WO2007040636A1 (en) 2005-09-29 2006-05-05 Methods for reducing blood pressure

Publications (1)

Publication Number Publication Date
DE602006021600D1 true DE602006021600D1 (de) 2011-06-09

Family

ID=36971225

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006021600T Active DE602006021600D1 (de) 2005-09-29 2006-05-05 Verfahren zur senkung des blutdrucks

Country Status (11)

Country Link
US (1) US20070072817A1 (de)
EP (1) EP1942985B1 (de)
JP (1) JP2009510056A (de)
CN (1) CN101316626A (de)
AT (1) ATE507243T1 (de)
AU (1) AU2006297839B2 (de)
CA (1) CA2623693A1 (de)
DE (1) DE602006021600D1 (de)
HK (1) HK1121083A1 (de)
IL (1) IL190496A0 (de)
WO (1) WO2007040636A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591416A (en) 2008-08-25 2012-11-30 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
PL2670411T3 (pl) 2011-02-02 2019-09-30 Excaliard Pharmaceuticals, Inc. Związki antysensowne ukierunkowane na czynnik wzrostu tkanki łącznej (ctgf) do leczenia bliznowców lub blizn przerostowych
BR112016013961A2 (pt) 2013-12-18 2017-10-10 The George Washington Univ A Congressional Chartered Not For Profit Corporation angiotensina ii sozinha ou em combinação para o tratamento da hipotensão
WO2016007589A1 (en) * 2014-07-08 2016-01-14 La Jolla Pharmaceutical Company Methods for treating hypotension
JP2019501201A (ja) 2016-01-07 2019-01-17 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ アンジオテンシンｉｉの投与方法
US11583568B2 (en) 2017-04-14 2023-02-21 La Jolla Pharma, Llc Methods for administering angiotensin II

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59227851A (ja) * 1983-06-09 1984-12-21 Sankyo Co Ltd レニン阻害作用を有するペプチド類
US4699905A (en) * 1984-04-10 1987-10-13 Sankyo Company, Limited Perhydrothiazepine derivatives, their preparation and their therapeutic use
US5194605A (en) * 1989-12-08 1993-03-16 Merck & Co., Inc. Cyclic renin inhibitors containing 2-substituted (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy pentanoic acid, 2-substituted (3S,4S)-5-cyclohexyl-3,4-di-hydroxy pentanoic acid or 2-substituted (4S,5S)-5-amino-6-cyclohexyl-4-hydroxyhexanoic acid or its analogs
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US6099869A (en) * 1995-04-18 2000-08-08 Nutrition 21 Calcium taurate and antihypertensive drug for hypertension
US5708029A (en) * 1995-11-13 1998-01-13 Vanmoor; Arthur High blood pressure relief method and compositions
AU5613999A (en) * 1998-09-18 2000-04-10 University Of British Columbia, The Pharmaceutical compositions of vanadium biguanide complexes and their use
IL151369A0 (en) * 2000-03-09 2003-04-10 Genzyme Corp USE OF TGF-beta ANTAGONISTS FOR PREPARATION OF A PHARMACEUTICAL COMPOSITION
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US20100004304A1 (en) * 2004-03-16 2010-01-07 Kohn Leonard D Methods and compositions for the treatment of malignant melanoma, breast, prostate, colon, papillary thyroid and pancreatic cancer
EP1865913A1 (de) * 2005-03-11 2007-12-19 Elixir Pharmaceuticals, Inc. Nad-bindende sirt-hemmer
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism

Also Published As

Publication number Publication date
HK1121083A1 (en) 2009-04-17
CN101316626A (zh) 2008-12-03
CA2623693A1 (en) 2007-04-12
EP1942985A1 (de) 2008-07-16
ATE507243T1 (de) 2011-05-15
EP1942985B1 (de) 2011-04-27
AU2006297839B2 (en) 2011-04-14
WO2007040636A1 (en) 2007-04-12
AU2006297839A1 (en) 2007-04-12
JP2009510056A (ja) 2009-03-12
IL190496A0 (en) 2008-11-03
US20070072817A1 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
EP2068768A4 (de) Verfahren und system zur verbesserung der diastolischen herzfunktion
DE602006021600D1 (de) Verfahren zur senkung des blutdrucks
EA200701995A1 (ru) Способы уменьшения кальцификации
TW200716646A (en) (S)-N-methylnaltrexone
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
DK2324871T4 (da) Citratantikoaguleringssystem til ekstrakorporale blodbehandlinger
EA200802213A1 (ru) Способы лечения заболеваний крови
DK3357911T3 (da) Prolylhydroxylaseinhibitorer og fremgangsmåder til anvendelse
ATE470354T1 (de) Systeme und verfahren für die ex-vivo-organpflege
ITMO20040191A1 (it) Macchina e metodo per il trattamento extracorporeo di sangue.
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
DE602005024846D1 (de) Blutdialysator
DE602006011828D1 (de) Methoden zur Herstellung von Katheterschaftröhren
WO2007056681A3 (en) Methods for administering hypoglycemic agents
DE602005026030D1 (de) Blutdruckmessgerät
NO20076241L (no) Terapier for vaskulaere sykdommer
SMT201300116B (it) Procedimenti e intermedi per la preparazione di uninibitore macrociclico di proteasi di hcv
ATE530660T1 (de) Enzymatische herstellung von (meth)acrylsäureestern
WO2007038264A3 (en) Gapr-1 methods
SG156636A1 (en) Carboxylic acid peri -substituted bicyclics for occlusive artery disease
NO20076405L (no) Anvendelse av 24-nor-UDCA
WO2006019978A3 (en) Compositions and methods for diagnosis and treatment of epilepsy
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
ZA200708576B (en) Blood pressure lowering protein hydrolysates